WO2007107679A2 - Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines - Google Patents
Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines Download PDFInfo
- Publication number
- WO2007107679A2 WO2007107679A2 PCT/FR2007/050986 FR2007050986W WO2007107679A2 WO 2007107679 A2 WO2007107679 A2 WO 2007107679A2 FR 2007050986 W FR2007050986 W FR 2007050986W WO 2007107679 A2 WO2007107679 A2 WO 2007107679A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- weight
- equal
- mixture
- cyclodextrins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L91/00—Compositions of oils, fats or waxes; Compositions of derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend
Definitions
- the present invention relates to the field of cosmetic, pharmaceutical, food, nutritional, nutraceutical and veterinary compositions.
- the invention relates to inclusion complexes of oleaginous substance (s), in particular of fatty acids, and a mixture of cyclodextrins, compositions comprising them and a process for the preparation of such complexes.
- s oleaginous substance
- the invention also relates to compositions comprising at least two cyclodextrins and at least one oleaginous substance.
- Oleaginous substances and in particular unsaturated fatty acids, can play a very important role in the body. For example, they may have an influence in: - cellular activity and humoral immunity,
- the organism in particular human, may have deficiencies in terms of unsaturated fatty acids, it may be useful to provide it.
- these fatty acids may have a specific taste and / or odor.
- Patent FR 2 547 829 proposes a composition containing unsaturated fatty acid compounds and a type of cyclodextrin whose role is to stabilize fatty acids and reduce the odor and bitterness associated with polyunsaturated fatty acids.
- EP 0 470 452 discloses a product comprising gamma-cyclodextrin for complexing an oleaginous substance containing a mixture EPA and DHA, polyunsaturated fatty acids of different structures.
- US 5189149 and US 6878696 disclose a method of encapsulating polyunsaturated fatty acid-rich animal or plant oils and their derivatives using a type of cyclodextrin. However, the protection of oils composed of a mixture of different polyunsaturated fatty acids may be insufficient.
- Patent FR 2,850,040 for its part describes an acid complex with alpha-cyclodextrin alone.
- inclusion complexes described above may have insufficient stability, or insufficiently mask the taste and / or odor of certain types of oleaginous substances, such as fatty acids.
- the subject of the invention is a mixture of inclusion complexes comprising, or consisting of:
- cyclodextrins chosen from alpha-, beta- and gamma-cyclodextrin and / or their derivatives, in particular their modified derivatives on the primary and / or secondary hydroxyl groups, and
- At least one oleaginous substance chosen especially from oils of animal, plant and synthetic origin.
- the mixture of complexes according to the invention may comprise an oleaginous substance content greater than or equal to 40% by weight, in particular greater than or equal to 50% by weight, in particular greater than or equal to 60% by weight, or even greater than or equal to 70% by weight relative to the total weight of complexes.
- the oleaginous substance may especially comprise or consist of at least one fatty acid, especially saturated and / or unsaturated fatty acid, a corresponding ester or triglyceride, in particular a mono- or poly-unsaturated fatty acid.
- fatty acids is intended to mean carboxylic acids comprising from 6 to 50 carbon atoms, in particular from 10 to 30 carbon atoms, and in particular from 12 to 22 carbon atoms.
- the name of this class of compounds recalls their natural origin, the fatty substances, which are esters of long-chain carboxylic acids, in particular fats of animal or vegetable origin which can be triesters of glycerol.
- unsaturated fatty acids means monounsaturated or polyunsaturated fatty acids.
- the fatty acid may come from a vegetable, animal or synthetic oil or a mixture thereof, in particular from fish oil, linseed oil and / or camelina oil, and in particular the fatty acid may be from an oil selected from the group consisting of:
- linseed oil which may comprise an alpha-linolenic acid content of about 56%
- nut, rapeseed and soybean oil which may comprise an alpha-linolenic acid content ranging from 8% to 14%
- - blackcurrant seed oil which may comprise about 12 to 24% linoleic acid, 15 to 19% gamma-linolenic acid but also 30 to 40% alpha-linolenic acid and 3 to 4 % of stearidonic acid (omega 3),
- camelina oil which may contain 12 to 24% linoleic acid, but also 30 to 40% alpha-linolenic acid, 10 to 24% oleic acid and 500 to 800 mg / kg of tocopherol and tocorienol,
- - Corn, sunflower and grapeseed oils which can be very rich, especially in linoleic acid, and - fish oils, which may contain large proportions of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- the oleaginous substance may comprise an unsaturated fatty acid content greater than or equal to 30% by weight, in particular greater than or equal to 50% by weight, in particular greater than or equal to 70% by particular weight, more particularly greater than or equal to 90% by weight.
- % by weight or even greater than or equal to 95% by weight, relative to the total weight of oleaginous substance.
- Unsaturated fatty acids include fatty acids selected from the group consisting of:
- docosene-13-oic acid 22: 1, omega-9
- the oleaginous substance may comprise a content of omega fatty acid (s), in particular omega-3, omega-6 and / or omega-9, greater than or equal to 50% by weight, in particular greater than or equal to 75% by weight. weight, in particular greater than or equal to 90% weight, or even greater than or equal to 99% by weight relative to the total weight of oleaginous substance.
- omega fatty acid s
- omega-3, omega-6 and / or omega-9 greater than or equal to 50% by weight, in particular greater than or equal to 75% by weight.
- weight in particular greater than or equal to 90% weight, or even greater than or equal to 99% by weight relative to the total weight of oleaginous substance.
- Natural cyclodextrins (alpha, beta and gamma) are most often derived from the bioconversion of maize starch by a bacterial enzyme, cycloglycosyltransferase (CGTase).
- cyclic oligosaccharides having respectively, for alpha, beta and gamma: 6, 7 or 8 alpha-D-glucopyranose units, the bonds connecting these units are of the alpha- (1 4) glucosidic type.
- Aqueous solubility (g / 100 14.5 1.85 23.2 mL, 25 ° C)
- the cyclodextrin derivatives can be obtained by substitution of primary or secondary hydroxyl groups, for example by alkyl radicals, in particular comprising from 1 to 12 carbon atoms, for example methyl (-CH 3 ) or propyl (-C 3 H 9 ) . These substitutions may make it possible to increase the lipophilicity of the cavity and increase the aqueous solubility of the cyclodextrin.
- the structure of cyclodextrins can be represented as a conical trunk with a hydrophobic cavity.
- the exterior of the cyclodextrin molecule is generally hydrophilic, they are pseudo-amphiphilic molecules.
- This pseudo-amphiphilic structure can allow the formation of inclusion complexes.
- the inclusion complex may have physicochemical properties independent of the guest molecule and thus improve the apparent solubility in water of this molecule.
- This improvement in solubility may allow, for example, an improvement in the bioavailability of the molecule, in particular by improving the dissolution rate of the molecule.
- the mixture of complexes according to the invention comprises at least two different cyclodextrins, which may each be present in a content greater than or equal to 1% by weight, especially at a content greater than or equal to 10% by weight, or even a higher content. or equal to 20% by weight, or even a content greater than or equal to 30% relative to the total weight of cyclodextrin.
- the mixture of complexes comprises two cyclodextrins, in particular: an alpha-cyclodextrin / beta-cyclodextrin mixture, in particular in a ratio ranging from 10/1 to 1/10, or even from 4/1 to 1/4,
- an alpha-cyclodextrin / gamma-cyclodextrin mixture in particular in a ratio ranging from 10/1 to 1/10, or even from 4/1 to 1/4, or a beta-cyclodextrin / gamma-cyclodextrin mixture, in particular in a ratio ranging from 10/1 to 1/10, or even from 4/1 to 1/4.
- the mixture of complexes comprises three cyclodextrins, in particular an alpha-cyclodextrin / beta-cyclodextrin / gamma-cyclodextrin mixture, in particular with an alpha-cyclodextrin / beta-cyclodextrin ratio ranging from 10/1 to 1/10, or even from 4/1 to 1/4, with an alpha-cyclodextrin / gamma-cyclodextrin ratio ranging from 10/1 to 1/10, or even from 4/1 to 1/4, and / or with a beta-cyclodextrin / gamma-cyclodextrin ratio ranging from 10/1 to 1/10, or even 4/1 to 1/4.
- the subject of the invention is also a composition
- a composition comprising or consisting of a mixture of at least two cyclodextrins chosen from alpha-, beta- and gamma-cyclodextrin and / or their derivatives, and at least one oleaginous substance.
- This composition may have an oleaginous substance / cyclodextrin weight ratio greater than or equal to 0.5, in particular greater than or equal to 1, or even greater than or equal to 2.
- the composition comprises an oleaginous substance content greater than or equal to 10% by weight, in particular greater than or equal to 20% by weight, advantageously greater than or equal to 30% by weight, in particular greater than or equal to 40% by weight, more especially greater than or equal to 50% by weight, especially greater than or equal to 60% by weight, or even greater than or equal to 70% by weight relative to the total weight of the composition.
- the composition may comprise at least two different cyclodextrins, each present in a content greater than or equal to 1% by weight, especially at a content greater than or equal to 10% by weight, or even a content greater than or equal to 20% by weight, even at a content greater than or equal to 30% relative to the total weight of cyclodextrin.
- the composition comprises inclusion complexes according to the invention, especially in a content ranging from 1 to 99.9% by weight, in particular ranging from 15 to 99% by weight, or even from 25 to at 95% by weight relative to the total weight of the composition.
- composition according to the invention may be in the form of a liquid, in particular aqueous, a semi-solid, a solid. It may especially be in the form of a powder, tablets, capsules, a cream, an emulsion, especially oil-in-water or water-in-oil, or even a multiple emulsion, liposomes, nanoparticles, microparticles or a suspension.
- compositions according to the invention may be pharmaceutical, nutritional, veterinary, nutraceutical, food or cosmetic compositions comprising a mixture of inclusion complexes according to the invention.
- inclusion of oleaginous substance, and in particular of fatty acids, in particular polyunsaturated fatty acids, or of their triglycerides, salts and / or esters in mixtures of cyclodextrins, according to the invention may make it possible to obtain aqueous, solid formulations or semi-solid, at 20 ° C.
- this oleaginous substance and in particular these polyunsaturated fatty acids and / or their triglycerides, salts and esters while suppressing or greatly reducing the problems related to their oxidability and their instability as well as reducing or eliminating their taste and / or smell.
- the subject of the invention is also the use of a mixture of at least two cyclodextrins as an agent for stabilizing and / or masking the taste and / or odor of oleaginous substance, in particular of acid unsaturated fats, in a composition, especially food, nutraceutical, cosmetic, pharmaceutical, veterinary, further comprising at least one oleaginous substance.
- the subject of the invention is also the use of a mixture of at least two cyclodextrins and an oleaginous substance, in particular at least one unsaturated fatty acid, for the preparation of a medicinal product, in particular intended to treat or to prevent cardiovascular diseases.
- the subject of the invention is a method for preparing inclusion complexes comprising at least the steps of: solubilizing at least two cyclodextrins chosen from alpha-, beta- and gamma-cyclodextrin and / or their derivatives, in particular in degassed water
- the mixture is agitated, in particular under an inert atmosphere and / or absence of light, in particular at a temperature ranging from 10 to 40 ° C.,
- the complexes can be recovered directly in emulsion form, or in powder form, in particular by lyophilization of the emulsion or by spray drying.
- Example 1 Inclusion complexes of 60% camelina oil with a binary mixture of 40% cyclodextrins composed of 50% alpha-cyclodextrin and 50% ⁇ -cyclodextrin.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 2 Inclusion complexes of 60% camelina oil with a binary mixture of 40% cyclodextrins composed of 30% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.75 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved. 1.5 g of camelina oil are then added, and stirring is maintained constant at 300 rpm in the absence of light on a turntable for 24 hours at room temperature. A stable white suspension consisting of 40% binary mixture of cyclodextrin and 60% camelina oil is formed.
- Example 3 Inclusion complexes of 70% camelina oil with a binary mixture of 30% cyclodextrins composed of 15% ⁇ -cyclodextrin and 15% ⁇ -cyclodextrin.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 4 Inclusion complexes of 70% camelina oil with a binary mixture of 30% cyclodextrins composed of 20% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.5 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved. 1.75 g of camelina oil are then added, and stirring is kept constant at 300 rpm in the absence of light on a turntable for 24 hours at room temperature. A stable white suspension consisting of 30% binary mixture of cyclodextrin and 70% camelina oil is formed.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 5 Inclusion complexes of 80% of camelina oil with a binary mixture of 20% cyclodextrins composed of 10% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.25 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- Example 6 Inclusion complexes of 80% of camelina oil with a binary mixture of 20% of cyclodextrins composed of 15% of ⁇ -cyclodextrin and 5% of ⁇ -cyclodextrin.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 7 Inclusion complexes of 60% camelina oil with a binary mixture of 40% cyclodextrins composed of 20% ⁇ -cyclodextrin and 20% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.5 g of ⁇ -cyclodextrin and 0.5 g is introduced into a container.
- ⁇ -cyclodextrin and 30 ml degassed water The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 8 60% inclusion complexes of camelina oil with a binary mixture of 40% cyclodextrins composed of 30% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.75 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 9 Inclusion complexes of 70% camelina oil with a binary mixture of 30% cyclodextrins composed of 15% ⁇ -cyclodextrin and 15% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.375 g of ⁇ -cyclodextrin and 0.375 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- Example 10 Inclusion complexes of 70% camelina oil with a binary mixture of 30% cyclodextrins composed of 20% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin. 0.75 g of the cyclodextrin mixture composed of 0.5 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- Example 11 Inclusion complexes of 80% camelina oil with a binary mixture of 20% cyclodextrins composed of 10% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.25 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- Example 12 Inclusion complexes of 80% of camelina oil with a binary mixture of 20% cyclodextrins composed of 15% ⁇ -cyclodextrin and 5% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.375 g of ⁇ -cyclodextrin and 0.125 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a vessel. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 13 Inclusion Complexes of 60% camelina oil with a ternary mixture of 40% of cyclodextrins composed of 15% ⁇ -cyclodextrin, 10% ⁇ -cyclodextrin and 15% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.375 g of ⁇ -cyclodextrin, 0.25 g of ⁇ -cyclodextrin and 0.375 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved. 1.5 g of camelina oil are then added, and stirring is maintained constant at 300 rpm in the absence of light on a turntable for 24 hours at room temperature. A stable white suspension consisting of 40% binary mixture of cyclodextrin and 60% camelina oil is formed.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 14 Inclusion complexes of 70% camelina oil with a ternary mixture of 30% cyclodextrins composed of 10% ⁇ -cyclodextrin, 10% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.25 g of ⁇ -cyclodextrin, 0.25 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. . The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 15 Inclusion complexes of 79% of camelina oil by a ternary mixture of 21% of cyclodextrins composed of 7% ⁇ -cyclodextrin, 7% ⁇ -cyclodextrin and 7% ⁇ -cyclodextrin.
- cyclodextrin mixture consisting of 0.175 g of ⁇ -cyclodextrin, 0.175 g of ⁇ -cyclodextrin and 0.175 g of ⁇ -cyclodextrin are introduced into a container and 30 ml of degassed water. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 16 60% inclusion complexes of argan oil with a binary mixture of 40% cyclodextrins composed of 30% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.75 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 17 Inclusion complexes of 70% argan oil with a binary mixture of 30% cyclodextrins composed of 15% ⁇ -cyclodextrin and 15% ⁇ -cyclodextrin.
- Example 18 Inclusion complexes of 70% argan oil with a binary mixture of 30% cyclodextrins composed of 20% ⁇ -cyclodextrin and 10% ⁇ -cyclodextrin. 0.75 g of the cyclodextrin mixture composed of 0.5 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- a stable white suspension is formed consisting of 30% binary mixture of cyclodextrin and 70% argan oil.
- Example 19 60% inclusion complexes of argan oil with a ternary mixture of 40% of cyclodextrins composed of 15% of ⁇ -cyclodextrin, 10% of ⁇ -cyclodextrin and 15% of ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.375 g of ⁇ -cyclodextrin, 0.25 g of ⁇ -cyclodextrin and 0.375 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved. 1.5 g of argan oil are then added, and stirring is kept constant at 300 rpm in the absence of light on a turntable during 24 hours. hours, at room temperature. A stable white suspension is formed consisting of 40% binary mixture of cyclodextrin and 60% argan oil.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
- Example 20 Inclusion complexes of 70% of argan oil by a ternary mixture of 30% of cyclodextrins composed of 10% of ⁇ -cyclodextrin, 10% of ⁇ -cyclodextrin and 10% of ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.25 g of ⁇ -cyclodextrin, 0.25 g of ⁇ -cyclodextrin and 0.25 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- a stable white suspension is formed consisting of 30% binary mixture of cyclodextrin and 70% argan oil.
- Example 21 Inclusion complexes of 79% of argan oil by a ternary mixture of 21% of cyclodextrins composed of 7% of ⁇ -cyclodextrin, 7% of ⁇ -cyclodextrin and 7% of ⁇ -cyclodextrin.
- cyclodextrin mixture composed of 0.175 g of ⁇ -cyclodextrin, 0.175 g of ⁇ -cyclodextrin and 0.175 g of ⁇ -cyclodextrin and 30 ml of degassed water are introduced into a container. The whole is stirred on a turntable at 300 rpm until the mixture of cyclodextrins has completely dissolved.
- solubility of the lyophilized complexes is then examined, by dissolving in water, it leads to an opalescent solution.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Nanotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/225,499 US20090130218A1 (en) | 2006-03-23 | 2007-03-22 | Association of Oleaginous Substance With a Mixture of at Least Two Cyclodextrins |
| JP2009500900A JP2009530357A (ja) | 2006-03-23 | 2007-03-22 | 2つ以上のシクロデキストリンからなる混合物と油性物質との会合 |
| CA002647089A CA2647089A1 (fr) | 2006-03-23 | 2007-03-22 | Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines |
| EP07731799A EP2003990A2 (fr) | 2006-03-23 | 2007-03-22 | Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0602526 | 2006-03-23 | ||
| FR0602526A FR2898817B1 (fr) | 2006-03-23 | 2006-03-23 | Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007107679A2 true WO2007107679A2 (fr) | 2007-09-27 |
| WO2007107679A3 WO2007107679A3 (fr) | 2007-11-15 |
Family
ID=37461380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2007/050986 Ceased WO2007107679A2 (fr) | 2006-03-23 | 2007-03-22 | Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090130218A1 (fr) |
| EP (1) | EP2003990A2 (fr) |
| JP (1) | JP2009530357A (fr) |
| CA (1) | CA2647089A1 (fr) |
| FR (1) | FR2898817B1 (fr) |
| WO (1) | WO2007107679A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100291206A1 (en) * | 2007-05-31 | 2010-11-18 | Jo Klaveness | Oral dosage form |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009078030A1 (fr) * | 2007-12-17 | 2009-06-25 | Alkem Laboratories Limited | Substitut de graisse |
| US10328152B2 (en) | 2011-06-16 | 2019-06-25 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
| FR2999924B1 (fr) * | 2012-12-21 | 2015-07-17 | Oreal | Association d'actifs comprenant au moins une huile essentielle, une cyclodextrine et un corps gras liquide et composition la contenant. |
| FR3009504B1 (fr) * | 2013-08-12 | 2025-10-24 | In Cyclo | Nouveau systeme solide instantane auto-emulsionnant a base de cyclodextrines et d'huile pour l'administration orale |
| AR105019A1 (es) * | 2015-06-25 | 2017-08-30 | Acraf | COMPOSICIÓN DESODORANTE QUE COMPRENDE DE UNA MEZCLA DE CICLODEXTRINA a, b Y g |
| JP6855001B2 (ja) * | 2016-11-24 | 2021-04-07 | 池田食研株式会社 | 油溶性物質含浸食品の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5423966B2 (fr) * | 1972-11-11 | 1979-08-17 | ||
| HU176217B (en) * | 1978-11-20 | 1981-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing a cyclodextrin-chamomille inclusion complex and compositions containing thereof |
| JPS5921613A (ja) * | 1982-07-28 | 1984-02-03 | Takeda Chem Ind Ltd | 直腸投与製剤 |
| GB2140806B (en) * | 1983-05-28 | 1987-10-28 | Sekimoto Hiroshi | Stabilisation of unsaturated fatty acids, fish oils or fish |
| JPS6058973A (ja) * | 1983-09-13 | 1985-04-05 | Mitsubishi Yuka Yakuhin Kk | γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤 |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| JPS636196A (ja) * | 1986-06-26 | 1988-01-12 | 柴内 裕子 | 紙の製造方法 |
| IT1243192B (it) * | 1990-08-09 | 1994-05-24 | Staroil Ltd | Complessi di acidi grassi polinsaturi a lunga catena e di loro derivati, con ciclodestrine |
| FR2692168B1 (fr) * | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| US7799365B2 (en) * | 2001-04-06 | 2010-09-21 | Burnbrae Farms Limited | Liquid egg composition including fish oil with omega-3 fatty acid |
| US7105195B2 (en) * | 2003-07-25 | 2006-09-12 | General Mills, Inc. | Reduced trans fat product |
| CA2523390A1 (fr) * | 2004-10-15 | 2006-04-15 | General Mills, Inc. | Mais souffle au four a micro-ondes avec thaumatine et methode de preparation |
-
2006
- 2006-03-23 FR FR0602526A patent/FR2898817B1/fr not_active Expired - Fee Related
-
2007
- 2007-03-22 US US12/225,499 patent/US20090130218A1/en not_active Abandoned
- 2007-03-22 EP EP07731799A patent/EP2003990A2/fr not_active Withdrawn
- 2007-03-22 JP JP2009500900A patent/JP2009530357A/ja not_active Withdrawn
- 2007-03-22 CA CA002647089A patent/CA2647089A1/fr not_active Abandoned
- 2007-03-22 WO PCT/FR2007/050986 patent/WO2007107679A2/fr not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100291206A1 (en) * | 2007-05-31 | 2010-11-18 | Jo Klaveness | Oral dosage form |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2898817A1 (fr) | 2007-09-28 |
| WO2007107679A3 (fr) | 2007-11-15 |
| US20090130218A1 (en) | 2009-05-21 |
| FR2898817B1 (fr) | 2008-08-08 |
| JP2009530357A (ja) | 2009-08-27 |
| CA2647089A1 (fr) | 2007-09-27 |
| EP2003990A2 (fr) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526033A (ja) | オメガ3 | |
| EP2003990A2 (fr) | Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines | |
| CA2044290A1 (fr) | Microcapsule de liquide huileux | |
| FR2547829A1 (fr) | Compositions contenant des composes d'acides gras insatures et procede de stabilisation de tels composes | |
| EP0796238B1 (fr) | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises en therapeutique et en cosmetologie | |
| EP1035846A2 (fr) | Agnim comme agents anti-inflammatoires dans les tissus superficiels des mammiferes | |
| WO1996002488A9 (fr) | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises en therapeutique et en cosmetologie | |
| CA2325887A1 (fr) | Procede d'obtention d'une huile enrichie en acides gras hydroxyoctadecadienoiques (hode) ou de ses esters, a partir d'un melange huileux contenant de l'acide linoleique, ou ses esters | |
| WO2015022454A1 (fr) | Nouveau systeme solide instantane auto-emulsionnant a base de cyclodextrines et d'huile (s) pour l'administration orale | |
| EP1165620A1 (fr) | Complexes d'inclusion d'acides gras polyinsatures et de leurs derives avec la y-cyclodextrine | |
| EP1950210B1 (fr) | Utilisation de dérivés polyphénoliques liposolubles comme antioxydants | |
| BE1011077A3 (fr) | Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes. | |
| FR2924428A1 (fr) | Pseudo-ceramides derives d'huiles vegetales et les compositions cosmetiques et/ou dermatologiques en contenant | |
| FR2741533A1 (fr) | Procede de stabilisation des acides gras polyinsatures et utilisation de ces produits stabilises en cosmetologie | |
| FR2915901A1 (fr) | Composition homogene et stable, riche en substances oleagineuses a base d'un produit laitier, son procede de preparation et ses utilisations. | |
| EP2273895A1 (fr) | Compositions comprenant de l'acide myristique, des acides gras comprenant un diene conjugue n-5cis, n-7trans ou un triene conjugue n-5cis, n-7trans, n-9cis | |
| US7740885B2 (en) | Nutraceutical and pharmaceutical compositions and their uses | |
| FR2893026A1 (fr) | Nouveaux derives polyphenoliques liposolubles et leur utilisation comme antioxidants | |
| FR2865353A1 (fr) | Nouveaux complements dietetiques ou alimentaires a base d'acide gras insature et leurs utilisation | |
| GB2633109A (en) | Method of forming a liposome comprising a derivative of curcumin | |
| FR3148365A1 (fr) | Oxylipines dans le traitement de la séborrhée et/ou de l’acné | |
| EP1677622A1 (fr) | Procede zootechnique pour l' administration d'un derive de vitamine e et formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007731799 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2009500900 Country of ref document: JP Ref document number: 2647089 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07731799 Country of ref document: EP Kind code of ref document: A2 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12225499 Country of ref document: US |